transplantation (HSCT) [2] , may, however, have dramatic cardiac consequences.
We retrospectively evaluated the evolution of cardiac function in seven patients with secondary AML to breast cancer. All patients had previously received fluorouracil, epirubicin and cyclophosphamide chemotherapy regimen and radiation therapy. Median age at AML presentation was 49 years (range 43-56). All patients except one (who received HSCT at relapse) had intermediate or high-risk cytogenetic abnormalities. All except one, who went directly through an allogeneic genoidentical HSCT after myeloablative conditioning, received a combination chemotherapy regimen including daunorubicin, cytarabin and etoposide for AML induction and consolidation. Those patients received cumulative equivalent daunorubicin doses above the 450 mg/ m 2 recognised cardiotoxic threshold. Three patients were intensified with one or two (in one case after relapse) genoidentical allogeneic HSCT after reduced conditioning regimen. One patient was autografted. No anthracyclinespecific cardioprotective agents were administered during AML treatment.
Although neither cardiovascular disease nor decreased left ventricular ejection fraction (LVEF) below 50%, estimated by transthoracic echocardiography examination, were observed before AML treatment, all patients who received anthracyclines for AML treatment (six of seven) developed transient (two of six) or definitive (four of six) cardiac dysfunction with a significant drop in their LVEF ( Table 1) . The severity of cardiac heart failure according to the National Cancer Institute Toxicity Criteria was of grade 3 to 4 in most cases, some of them required transient mechanical ventilation and catecholamine administration and one died. The only patient exempt from cardiac complication had not received anthracyclines for AML treatment. Moreover, four of the five transplanted patients developed severe heart failure, among which two were fatal, despite the introduction of cardiac treatment before HSCT in three of them. All of those had received a cumulative anthracycline dose above the toxic threshold. Therefore, anthracyclineinduced cardiotoxicity might increase the toxicity-related mortality of allogeneic HSCT in these patients. Our results are in contrast to those of Lehman et al. [3] , who did not find a significant decline in cardiac function after allogeneic HSCT, even in patients who had previously received anthracyclines and/or had developed AML secondary to breast cancer therapy. This might be explained by the use of lower cumulative doses of anthracycline in their series. We conclude that treatment strategy of secondary AML to breast cancer must take into account this life-threatening complication. One may consider the systematic use of cardioprotective drugs such as dexrazoxane [4] , although they have not yet been evaluated in AML, or that of anthracycline-free chemotherapy regimen such as the association of cytarabine and clofarabine [5] . In addition, a close monitoring of cardiac function using troponine I and BNP (brain natriuretic peptide) combined to the better available technique to measure LVEF is highly recommended in order to introduce specific cardiac treatments without delay. 
